function addBookmark(title, url) {

if (title == null) {
  title = window.document.title;
 }
 
 if (url == null) {
  url = window.document.location;
 }
 
 if ((navigator.appName == "Microsoft Internet Explorer") && (parseInt(navigator.appVersion) >= 4)) {
 window.external.AddFavorite(url,title);
 }
 
 else if ((navigator.appName == "Netscape") && (window.sidebar)) {
  window.sidebar.addPanel(title,url,"");
 } 
 else {
  alert("Press CTRL-D (Netscape/Safari) or CTRL-T (Opera) to bookmark");
 }
 
 return false;
}

function checkFontSelection() {
 var fontSize = readCookie("font_size");
 
 if (!fontSize || fontSize == "" || fontSize == "regular") {
  return;
 }
 
 else {
  setFontSize(fontSize);
 }
}

function setFontSize(newSize) {
 window.document.body.className = newSize;
 createCookie("font_size", newSize);
 
 return false;
}

function createCookie(name, value, days) {
 if (days) {
  var date = new Date();
  date.setTime(date.getTime() + (days*24*60*60*1000));
  var expires = "; expires=" + date.toGMTString();
 }
 else expires = "";
 
 document.cookie = name + "=" + value + expires + "; path=/";
}

function readCookie(name) {
 var nameEQ = name + "=";
 var ca = document.cookie.split(';');
 
 for (var i=0; i < ca.length; i++) {
  var c = ca[i];
  while (c.charAt(0) == ' ') c = c.substring(1, c.length);
  if (c.indexOf(nameEQ) == 0) return c.substring(nameEQ.length, c.length);
 }
 
 return null;
}

function showDisclaimer() {
 return confirm("Thank you for visiting.\nYou are now leaving BYSTOLIC.com. Forest Laboratories is not responsible for the content or services on the site you will now visit.");
}

function addDisclaimer() {
 var elements = (document.links) ? document.links : document.getElementsByTagName("a");
 var searchStr = "elements[i].href.search(/^" + document.location.protocol + "\\/\\/" + document.location.hostname + "(:\\d{2,4})?\\//)";
 
 for (var i = 0; i < elements.length; ++i) {
  if (elements[i].href && elements[i].href.search(/^javascript:/) == -1 && elements[i].href.search(/^mailto:/) == -1 && elements[i].href.search(/^https?:\/\/(www\.)?frx\.com/) == -1 && eval(searchStr) == -1) {
   elements[i].onclick = function() { return showDisclaimer(); };
  }
 }
}

/*
 var value1 = querySt("value1");
 if (value1=="runscript")
 {
    dcsMultiTrack('DCS.dcsuri','/flash/intro14.swf/Introduction','WT.ti','Intro');
 }
}

function querySt(ji) 
{
    hu = window.location.search.substring(1);
    gy = hu.split("&");
    for (i=0;i<gy.length;i++) 
    {
        ft = gy[i].split("=");
        if (ft[0] == ji) 
        {
            return ft[1];
        }
    }
}
*/

function writeSafetyInfo() {
 document.write("<h2>Important Safety Information</h2>");
 document.write("<p>Patients being treated with BYSTOLIC should be advised against abrupt discontinuation of therapy. Severe exacerbation of angina and the occurrence of myocardial infarction and ventricular arrhythmias have been reported following the abrupt cessation of therapy with beta blockers. When discontinuation is planned, the dosage should be reduced gradually over a 1- to 2-week period and the patient carefully monitored.</p>");document.write("<p>BYSTOLIC is contraindicated in severe bradycardia, heart block greater than first degree, cardiogenic shock, decompensated cardiac failure, sick sinus syndrome (unless a permanent pacemaker is in place), severe hepatic impairment (Child-Pugh &gt;B), and in patients who are hypersensitive to any component of this product.</p>");
document.write("<p>BYSTOLIC should be used with caution in patients with peripheral vascular disease, thyrotoxicosis, in patients treated concomitantly with beta blockers and calcium channel blockers of the verapamil and diltiazem type (ECG and blood pressure should be monitored), severe renal impairment, and any degree of hepatic impairment or in patients undergoing major surgery. In patients who have compensated congestive heart failure, BYSTOLIC should be administered cautiously. If heart failure worsens, discontinuation of BYSTOLIC should be considered. Caution should also be used in diabetic patients as beta blockers may mask some of the manifestations of hypoglycemia, particularly tachycardia.</p>");
document.write("<p>Use caution when BYSTOLIC is co-administered with CYP2D6 inhibitors (quinidine, propafenone, fluoxetine, paroxetine, etc). When BYSTOLIC is administered with fluoxetine, significant increases in d-nebivolol may be observed (ie, an 8-fold increase in AUC).</p>");
document.write("<p>In general, patients with bronchospastic disease should not receive beta blockers.</p>");
document.write("<p>BYSTOLIC should not be combined with other beta blockers.</p>");
document.write("<p>The most common adverse events with BYSTOLIC versus placebo (approximately ≥1% and greater than placebo) were headache, fatigue, dizziness, diarrhea, nausea, insomnia, chest pain, bradycardia, dyspnea, rash, and peripheral edema.</p>");
}


function ClearText(obj) { obj.value = ""; }
 
 
 function ImageLoad(n) {
    pic = new Image(1, 1);
    switch (n) {
        case 1:
            pic.src ="http://view.atdmt.com/action/BYS_CT_IRIblurb_PI"; break;
        case 2:
            pic.src ="http://view.atdmt.com/action/BYS_CT_IRIblurb_IRI";  break;
        case 3:
            pic.src ="http://view.atdmt.com/action/BYS_CT_BystolicEnEspanol";  break;
        case 4:
            pic.src = "http://view.atdmt.com/action/BYS_RightNav_TalkingToYourDoctor"; break;
        case 5:
            pic.src ="http://view.atdmt.com/action/BYS_RightNav_Email"; break;
        case 6:
            pic.src = "http://view.atdmt.com/action/BYS_RightNav_LearnMore"; break; 
           
}
 }